Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 255

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer

Open access
Sölétormos, György, Duffy, Michael J., Hassan, Suher Othman Abu, Verheijen, René H.M., Tholander, Bengt, Bast, Robert C., Gaarenstroom, Katja N., Sturgeon, Catharine M., Bonfrer, Johannes M., Petersen, Per Hyltoft, Troonen, Hugo, CarloTorre, Gian, Kulpa, Jan Kanty, Tuxen, Malgorzata K., Molina, Raphael·2016·International Journal of Gynecological Cancer

Abstract

OBJECTIVE: To present an update of the European Group on Tumor Markers guidelines for serum markers in epithelial ovarian cancer. METHODS: Systematic literature survey from 2008 to 2013. The articles were evaluated by level of evidence and strength of recommendation. RESULTS: Because of its low sensitivity (50-62% for early stage epithelial ovarian cancer) and limited specificity (94-98.5%), cancer antigen (CA) 125 (CA125) is not recommended as a screening test in asymptomatic women. The Risk of Malignancy Index, which includes CA125, transvaginal ultrasound, and menopausal status, is recommended for the differential diagnosis of a pelvic mass. Because human epididymis protein 4 has been reported to have superior specificity to CA125, especially in premenopausal women, it may be considered either alone or as part of the risk of ovarian malignancy algorithm, in the differential diagnosis of pelvic masses, especially in such women. CA125 should be used to monitor response to first-line chemotherapy using the previously published criteria of the Gynecological Cancer Intergroup, that is, at least a 50% reduction of a pretreatment sample of 70 kU/L or greater. The value of CA125 in posttherapy surveillance is less clear. Although a prospective randomized trial concluded that early administration of chemotherapy based on increasing CA125 levels had no effect on survival, European Group on Tumor Markers state that monitoring with CA125 in this situation should occur, especially if the patient is a candidate for secondary cytoreductive surgery. CONCLUSIONS: At present, CA125 remains the most important biomarker for epithelial ovarian cancer, excluding tumors of mucinous origin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/igc.0000000000000586

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 255

Metadata

Authors
Sölétormos, G., Duffy, M. J., Hassan, S. O. A., Verheijen, R. H. M., Tholander, B., Bast, R. C., Gaarenstroom, K. N., Sturgeon, C. M., Bonfrer, J. M., Petersen, P. H., Troonen, H., CarloTorre, G., Kulpa, J. K., Tuxen, M. K., & Molina, R.
Venue
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Published
2016-01
Volume
26
Issue
1
Pages
43-51
ISSN
1048-891X (ISSN-L)
OpenAlex
W2291806982
Cited by
255
References
52
FWCI
21.95
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer. https://app.cochat.ai/papers/10.1097/igc.0000000000000586
The paper
Sölétormos, G., Duffy, M. J., Hassan, S. O. A., Verheijen, R. H. M., Tholander, B., Bast, R. C., Gaarenstroom, K. N., Sturgeon, C. M., Bonfrer, J. M., Petersen, P. H., Troonen, H., CarloTorre, G., Kulpa, J. K., Tuxen, M. K., & Molina, R. (2016). Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer. https://doi.org/10.1097/igc.0000000000000586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.